Metabolic
Cagrilintide
Also called AM833
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 1.67mg/mL
- Volume per draw
- 0.18mL
- Units to dial
- 18
- Doses per cartridge
- 16
Vial label
Copy this into your label printer.
Published research contexts for Cagrilintide describe 0.3–4.5 mg per administration. Descriptive only, not a recommendation.
About 7–8 days; a long-acting amylin analog dosed once weekly.
Dosing schedule
How Cagrilintide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Weeks 1–2Start of the escalation; the phase-2 trial ramped over roughly 20 weeks. | 0.3 mg | Once weekly | SubQ |
| Weeks 3–4 | 0.6 mg | Once weekly | SubQ |
| Weeks 5–6 | 1.2 mg | Once weekly | SubQ |
| Weeks 7–8 | 2.4 mg | Once weekly | SubQ |
| Week 9+Highest step in the phase-2 trial; reached only as tolerated. | 4.5 mg | Once weekly | SubQ |
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 2.09× single dose
- Time to steady state
- 37.5days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Lau DCW et al., Lancet 2021;398:2160Phase-2 of once-weekly cagrilintide escalated across 0.3, 0.6, 1.2, 2.4 and 4.5 mg over about 20 weeks in adults with overweight or obesity.